1,553 results match your criteria Paronychia


Pediatric Hand Infections.

Authors:
Joseph F Styron

Hand Clin 2020 Aug;36(3):381-386

9500 Euclid Avenue Mail Code A40, Cleveland, OH 44195, USA. Electronic address:

Infections are an important source of morbidity in pediatric hands that come from frequent exposure to mouths and other dangers while exploring the world. Although Staphylococcus aureus is still the most common organism in pediatric hand infections, it is less common than in adults because pediatric patients are more likely to develop mixed aerobic/anaerobic infections or group A Streptococcus pyogenes infection. Pediatric patients with open physes potentially may sustain Seymour fractures of the distal phalanges that may become infected and sources for osteomyelitis if not recognized early. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hcl.2020.03.012DOI Listing

Fungal Infections of the Hand.

Hand Clin 2020 Aug;36(3):355-360

Department of Orthopaedic Surgery, Philadelphia Hand to Shoulder Center, Thomas Jefferson University, 834 Chestnut Street, Suite G-114, Philadelphia, PA 19107, USA.

Clinically significant fungal infections of the upper extremity are uncommon but increasing They are classified based on anatomic location and epidemiology. The anatomic categories that affect the hand include cutaneous, subcutaneous, and deep. Cutaneous infections are caused by organisms that metabolize keratin and can cause serious morbidity but are rarely fatal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hcl.2020.03.009DOI Listing

Fingertip Infections.

Hand Clin 2020 Aug;36(3):313-321

Division of Hand Surgery, Department of Orthopaedic Surgery, Massachusetts General Hospital, MGH Orthopaedic Hand Surgery, Yawkey Center for Outpatient Care, 55 Fruit Street, Suite 2C, Boston, MA 02114-2696, USA. Electronic address:

The fingertip is the most common site of infections in the hand, which frequently are encountered by surgeons, dermatologists, and emergency and primary providers. Their mismanagement may have serious consequences. This review discusses the unique anatomy of the volar fingertip pulp and perionychium and reviews pathophysiology and treatment of acute and chronic paronychia, including the decision for surgical versus medical management, choice of antibiotics, incisional techniques, and postincisional care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hcl.2020.03.004DOI Listing

Acute Paronychia and Reactive Capillary Proliferation in a Patient on Erlotinib.

Indian J Dermatol 2020 May-Jun;65(3):236-237

Department of Dermatology and STD, University College of Medical Sciences and GTB Hospital, New Delhi, India. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_348_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292448PMC

Nail Changes Induced by Chemotherapeutic Agents.

Indian J Dermatol 2020 May-Jun;65(3):193-198

Department of Dermatology, MLN Medical College, Allahabad, Uttar Pradesh, India.

Introduction: Nail toxicity is a relatively uncommon cutaneous adverse effect of chemotherapeutic agents. Rapidly dividing cells of the nail matrix are perturbed by the antimitotic activity of these agents. Although most of these changes are cosmetic and regress once the therapy is completed, a few of these adverse effects are challenging to manage and require temporary or permanent suspension of chemotherapeutic agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_37_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292457PMC

Clinical significance of Candida isolation from dystrophic fingernails.

Mycoses 2020 Jun 20. Epub 2020 Jun 20.

Department of Dermatology, Sheba Medical Center, Ramat-Gan, Israel.

Background: Candida onychomycosis mostly involves fingernails. Yet, in contrast to dermatophytes, Candida isolation from dystrophic fingernails does not prove casualty, as sample contamination and non-pathogenic Candida growth occur. Characterising treatment outcome of Candida-positive dystrophic nails is crucial to avoid unnecessary treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/myc.13133DOI Listing

Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).

Oncologist 2020 Jun 19. Epub 2020 Jun 19.

Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.

Lessons Learned: Low-dose afatinib maintenance treatment among patients with EGFR-mutated NSCLC achieved long-time to treatment failure with fewer treatment-related AEs without detracting from the therapeutic efficacy. This modified regimen represents a practical usage that balances effectiveness and safety.

Background: Although afatinib is an effective therapy for patients with EGFR-mutated non-small cell lung cancer (NSCLC), drug-related adverse events (AEs) have often necessitated dose reductions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0545DOI Listing

Metastatic Osteoarticular Infective Endocarditis by Methicillin-sensitive Staphylococcus Aureus.

Cureus 2020 May 14;12(5):e8124. Epub 2020 May 14.

Internal Medicine, Jersey Shore University Medical Center, Neptune City, USA.

Infective endocarditis (IE) is a well-known complication of bacteremia with high-risk microorganisms such as  and . Skin and soft tissue infections with Staphylococcus remain a significant cause of bacteremia and IE, even with proper prompt management of the source of infection and the absence of risk factors. Although methicillin-resistant is a well-known etiology for osteoarticular septic emboli in IE, healthcare providers should be aware of the hidden virulence of methicillin-sensitive  for metastatic osteoarticular infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292723PMC

Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.

Paediatr Drugs 2020 Jun 6. Epub 2020 Jun 6.

Department of Medicine, Surgery and Health Sciences, University of Trieste, Piazzale Europa 1, 34127, Trieste, Italy.

Background: Plexiform neurofibromas (PN) are congenital tumors that affect up to 50% of individuals with neurofibromatosis type 1. Despite their benign nature, they can grow rapidly and cause severe morbidities. Selumetinib, an inhibitor of mitogen-activated protein kinase (MEK) 1 and 2, was reported to induce a clinical response in pediatric subjects with inoperable PN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-020-00399-yDOI Listing

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment.

J Clin Med 2020 Jun 5;9(6). Epub 2020 Jun 5.

Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and efficacy in older patients. This phase II trial (jRCTs071180002) evaluated osimertinib in T790M mutation-positive Japanese patients who were ≥75 years old and had experienced relapse or progression after previous EGFR-TKI treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9061762DOI Listing

Cutaneous leishmaniasis: A great imitator.

Clin Dermatol 2020 Mar - Apr;38(2):140-151. Epub 2019 Oct 24.

Department of Dermatology, Akdeniz University, School of Medicine, Antalya, Turkey.

Cutaneous leishmaniasis (CL) is called "the great imitator," because it can mimic almost all types of dermatoses. This similarity may sometimes lead to misdiagnosis, resulting in inappropriate treatment and morbidities. Atypical forms occur due to the interaction between parasitic factors and the host immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.008DOI Listing
October 2019

Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib.

JAAD Case Rep 2020 Jun 25;6(6):569-571. Epub 2020 Apr 25.

Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265062PMC

Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.

Medicine (Baltimore) 2020 Jun;99(23):e20510

School of Nursing, College of Medicine, Chang Gung University.

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is the primary treatment option for patients with non-small cell lung cancer (NSCLC). However, one of the major adverse effects associated with this therapy is skin toxicity, which impacts the patient's quality of life. This study aimed to describe the severities and locations of skin toxicity, and to analyze their association with the quality of life in patients with advanced NSCLC who received EGFR-TKI therapy as first-line treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020510DOI Listing

First- and third- generation EGFR inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatologic reactions.

Br J Dermatol 2020 Jun 1. Epub 2020 Jun 1.

Department of Anesthesiology, Duke University School of Medicine, Durham, NC, 27701, USA.

Epidermal growth factor receptor (EGFR) inhibitors are used to treat several malignancies but notoriously exert dermatologic toxicities, reducing patient adherence. Despite targeting the same receptor, different EGFR inhibitors exhibit distinct toxicities. Up to 90% of patients on EGFR inhibitors present with a papulopustular rash, with varying severity and frequency depending on the inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19263DOI Listing

The Impact of Onychopathies on Quality of Life: A Hospital-based, Cross-sectional Study.

Indian Dermatol Online J 2020 Mar-Apr;11(2):187-194. Epub 2020 Mar 9.

Department of Dermatology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.

Background: Onychopathies or nail disorders are associated with social stigma and causes limitation of daily activities by hampering the function of both fingers and toes.

Aim: To evaluate the impact of onychopathies on quality of life (QoL) and compare the severity of impact on QoL in various nail disorders.

Materials And Methods: A hospital-based cross-sectional study consisting of 540 patients with onychopathies was conducted in the dermatology outpatient department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_272_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247629PMC

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.

JAMA Oncol 2020 May 14:e201250. Epub 2020 May 14.

Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.

Importance: Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation-positive non-small cell lung cancer is well established, optimal dosing remains to be established, especially in elderly or frail patients.

Objective: To investigate the efficacy and safety of low-dose erlotinib in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer.

Design, Setting, And Participants: Single-arm phase 2 trial with the Southwest Oncology Group (SWOG) 2-stage design that enrolled frail patients from 21 Japanese institutions after meeting the inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.1250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226294PMC

Management of Paronychia in Patients With Apert Syndrome.

Tech Hand Up Extrem Surg 2020 May 8. Epub 2020 May 8.

University of Pittsburgh Medical Center.

Apert syndrome is a complex congenital syndrome that includes bicoronal craniosynostosis, craniofacial dysmorphologies, cleft palate, hearing loss, spina bifida occulta, cardiac anomalies, and affects the upper and lower extremities-producing complex syndactyly in these patients. Management of the hands yields several challenges and mandates close follow-up to balance repair of complex polysyndactyly with other pressing interventions, such as posterior cranial vault distraction and surgical management of the airway. Our goals of therapy for the hands are to preserve 10 digits, provide sufficient soft tissue coverage, optimize hand function, and minimize the number of surgical interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BTH.0000000000000295DOI Listing

Pemphigus vegetans with paronychia-like changes resistant to rituximab therapy.

Dermatol Ther 2020 May 5:e13515. Epub 2020 May 5.

Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA.

Pemphigus vegetans (PVeg) is a clinical variant of pemphigus vulgaris (PV) that makes up about 2% of all cases. It is distinguished from PV by the presence of vegetative plaques that are usually found in the oral mucosa or intertriginous areas. PVeg can present as one of two clinical subtypes: Hallopeau type and Neumann type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13515DOI Listing

Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma.

EXCLI J 2020 28;19:230-238. Epub 2020 Feb 28.

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently recommended by international guidelines as first-line treatment in patients with advanced EGFR-mutant non-small-cell lung cancer. With the availability of drugs, more and more patients choose EGFR-TKI treatment. However, pharmaceutical drugs used in clinical practice have side effects, such as diarrhea, paronychia, and hepatotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17179/excli2019-1964DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105942PMC
February 2020

Phytochemicals, Antioxidant Activity and Ethnobotanical Uses of (L.) Del. Fruits from the Arid Zone of Mauritania, Northwest Africa.

Plants (Basel) 2020 Mar 24;9(3). Epub 2020 Mar 24.

Université de Nouakchott Al Aasriya, Faculté des Sciences et Techniques, Unité de recherche génomes et milieux, nouveau campus universitaire, Nouakchott, P.O. Box 880, Mauritanie.

Phytochemicals and antioxidant activity of fruits of 30 trees naturally growing in the hyper-arid and arid zones in Mauritania were evaluated by following standard procedures. Ethnobotanical uses of fruit pulps and kernel were assessed using a structured questionnaire. fruit pulp is a good source of sugars (33 g/100 g dry matter (DM)), polyphenols (264 mg GAE/100 g DM) and flavonoids (34. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/plants9030401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154911PMC

Carpal tunnel syndrome and associated nail changes: Review and examples from the author's practice.

J Am Acad Dermatol 2020 Mar 19. Epub 2020 Mar 19.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.

Carpal tunnel syndrome (CTS) is commonly seen by general practitioners and often presents with neurologic symptoms of nocturnal pain and paresthesia along the median nerve distribution. Approximately 20% of patients also present with cutaneous findings (ulcerations, blistering, sclerodactyly, nail dystrophy) characterizing a severe form called necrotic CTS. Necrotic CTS can also be associated with bone changes (acro-osteolysis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.03.023DOI Listing

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

N Engl J Med 2020 04 18;382(15):1430-1442. Epub 2020 Mar 18.

From the Pediatric Oncology Branch (A.M.G., P.L.W., E.D., P.W., S.M., M.C.R., D.C.P., A.C., J.T., O.K., J.G., B.C.W.) and the Clinical Pharmacology Program (C.J.P., W.D.F.), Center for Cancer Research, National Cancer Institute, and the Rehabilitation Medicine Department, Clinical Center (S.M.P), National Institutes of Health, Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick (A.B., K.H.), the Cancer Therapy Evaluation Program (M.S., L.A.D.) and the Biostatistics and Data Management Section, Center for Cancer Research (S.M.S., D.J.V.), National Cancer Institute, National Institutes of Health, Shady Grove, and Johns Hopkins University School of Medicine, Baltimore (J.O.B.) - all in Maryland; Children's Hospital of Philadelphia, Philadelphia (M.J.F., A.C.S.); Cincinnati Children's Hospital, Cincinnati (B.W.); Children's National Hospital, Washington, DC (A.K., M.B.); and Indiana University School of Medicine, Indianapolis (D.W.C., C.Z.).

Background: No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1.

Methods: We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical benefit. Children with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas received oral selumetinib twice daily at a dose of 25 mg per square meter of body-surface area on a continuous dosing schedule (28-day cycles). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1912735DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305659PMC

The treatment of onychogryphosis of hand nails by total matricectomy and dorsal V-Y advancement flap.

Authors:
Kaan Gürbüz

Jt Dis Relat Surg 2020 ;31(1):39-42

Department of Orthopedics and Traumatology, Kayseri City Hospital, Kayseri, Turkey.

Objectives: This study aims to report the outcomes of dorsal V-Y advancement flap technique used for the reconstruction of surgical defects following total matricectomy performed for the onychogryphosis of hand nails.

Patients And Methods: A total of 18 consecutive patients (10 males, 8 females; mean age 38.4 years; range, 24 to 41 years) with 20 onychogryphotic hand nails who underwent total matricectomy and dorsal V-Y advancement flap technique were analyzed retrospectively between June 2015 and March 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5606/ehc.2020.70611DOI Listing
January 2020

Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.

Cancer Sci 2020 May 14;111(5):1724-1738. Epub 2020 Apr 14.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of first-line oral dacomitinib 45 mg compared with oral gefitinib 250 mg, each once daily in 28-d cycles, in patients with EGFR-activating mutation-positive (EGFR-positive; exon 19 deletion or exon 21 L858R substitution mutations) advanced non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS; RECIST, version 1.1, by blinded independent review). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226281PMC

A Rare Case of Extensive Pemphigus Vegetans.

Indian Dermatol Online J 2020 Jan-Feb;11(1):87-90. Epub 2019 Sep 26.

Department of Pathology, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.

Pemphigus vegetans is a rare variant of pemphigus vulgaris characterized by pustules and/or papillomatous vegetations, preferentially affecting intertriginous and periorificial areas. It has two subtypes: Hallopeau variant and Neumann variant. Cerebriform tongue, a morphology with typical pattern of sulci and gyri over dorsum of the tongue, is a well-known sign in pemphigus vegetans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_83_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001410PMC
September 2019

Scanning Electron Microscopy of Erlotinib-induced Hair Changes: Pili Torti et Canaliculi.

Int J Trichology 2019 Nov-Dec;11(6):238-240

Dermatology League, Federal University of Pelotas, Brazil.

The cutaneous toxicity of the epidermal growth factor receptor inhibitors, such as erlotinib, is associated with a wide range of manifestations, such as papulopustular eruptions, xerosis, paronychia, and changes in the growth pattern of hair and nails. Hair manifestations are seen in 10%-20% of the patients. A female patient taking erlotinib for lung cancer for 8 months noticed that her scalp hair became rough on palpation and that her eyelashes were elongated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijt.ijt_98_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984046PMC
February 2020

The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation.

Skin Appendage Disord 2020 Jan 25;6(1):44-47. Epub 2019 Oct 25.

Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Gefitinib is a multi-target tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer. Papulo-pustular and/or paronychia, abnormalities in hair growth, itching, and dryness due to epidermal growth factor inhibitors - i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000503758DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995969PMC
January 2020

Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.

Skin Appendage Disord 2020 Jan 8;6(1):32-36. Epub 2019 Oct 8.

Department of Dermatology, Ankara Bilkent City Hospital, Ankara, Turkey.

Ibrutinib is an oral covalent inhibitor of the Bruton's tyrosine kinase pathway and is approved for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström's macroglobulinaemia. It is generally a drug of choice for high-risk patients with indolent lymphomas. The safety profile of ibrutinib appears to be tolerable, with well-known side effects such as infections and haematologic complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995981PMC
January 2020

Skin Infections and Outpatient Burn Management: Skin Infections in Patients With Diabetes.

Authors:
Maulik M Dhandha

FP Essent 2020 Feb;489:21-26

Maine-Dartmouth Family Medicine Residency, 15 East Chestnut St, Augusta, ME 04330.

Diabetes is associated with many complications, including foot ulcers. Individuals with diabetes have a 15% to 25% likelihood of developing a foot ulcer in their lifetime. The pathophysiologic mechanisms are multifactorial but the major etiologic factors are peripheral vascular disease and diabetic neuropathy. Read More

View Article

Download full-text PDF

Source
February 2020

Topical and device-based treatments for fungal infections of the toenails.

Cochrane Database Syst Rev 2020 01 16;1:CD012093. Epub 2020 Jan 16.

Campbell Collaboration, New Delhi, India.

Background: Onychomycosis refers to fungal infections of the nail apparatus that may cause pain, discomfort, and disfigurement. This is an update of a Cochrane Review published in 2007; a substantial amount of new research warrants a review exclusively on toenails.

Objectives: To assess the clinical and mycological effects of topical drugs and device-based therapies for toenail onychomycosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD012093.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984586PMC
January 2020

EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.

Support Care Cancer 2020 Jan 23. Epub 2020 Jan 23.

School of Nursing, College of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan.

Purpose: The purposes of this study were to assess the levels of symptom distress, body image, and epidermal growth factor receptor inhibitors (EGFRI)-associated health-related quality of life (QoL); identify the factors related to EGFRI-associated health-related QoL; and examine the differences in EGFRI-associated health-related QoL by grade of skin toxicity in mCRC patients receiving target therapy.

Methods: This cross-sectional study examined mCRC patients who received cetuximab-based target therapy from the oncology and CRC inpatient and outpatient departments of a medical center in northern Taiwan. Structured questionnaires were used to measure patients' symptom distress, body image, and EGFRI-associated health-related QoL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05321-3DOI Listing
January 2020

Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report.

Onco Targets Ther 2019 12;12:10897-10902. Epub 2019 Dec 12.

Department of Respiratory Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, People's Republic of China.

Purpose: mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases; however, until now, there are no approved standard targeted therapy for NSCLC patients harboring mutations.

Case Presentation: We present a 63-year-old male with a long smoking history, who was diagnosed with stage IV squamous cell lung cancer. After the failures of two lines of treatment with carboplatin plus gemcitabine and nidaplatin plus docetaxel, in turn, the patient received a next-generation sequencing of circulating tumor DNA to seek for potential treatment opportunities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S228726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913761PMC
December 2019

[Chronic paronychia and Candida: A descriptive and analytical study of 164 cases].

Ann Dermatol Venereol 2020 Feb 12;147(2):143-146. Epub 2019 Dec 12.

Service de dermatologie-vénérologie, CHU Ibn Rochd, quartier des Hopitaux, 20400 Casablanca, Maroc.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2019.11.006DOI Listing
February 2020

Afatinib in locally advanced/metastatic NSCLC harboring common mutations, after chemotherapy: a Phase IV study.

Lung Cancer Manag 2019 Sep 2;8(3):LMT15. Epub 2019 Sep 2.

Medical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt.

Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with mutation-positive (m+) non-small-cell lung cancer (NSCLC) following chemotherapy.

Patients & Methods: In this open-label, single-arm Phase IV study, patients with m+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/lmt-2019-0004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891940PMC
September 2019

Ungual Tuberculosis: A Unique Clinical Case.

Skin Appendage Disord 2019 Nov 4;5(6):386-389. Epub 2019 Sep 4.

Dermatology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.

Cutaneous manifestations of tuberculosis (TB) are rare, particularly from an exogenous source. Involvement of the nail apparatus is extremely rare and has only previously been reported as a secondary involvement. We report the case of a 76-year-old female patient referred to our department with onychodystrophy with purulent drainage of the first left finger, which had developed during the preceding year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883477PMC
November 2019

Nail Involvement during Pemphigus.

Skin Appendage Disord 2019 Nov 27;5(6):362-365. Epub 2019 Aug 27.

Department of Dermatology Venereology, Hospital Ibn Rochd, University Hassan II, Casablanca, Morocco.

Background: Pemphigus is an autoimmune bullous disease affecting the skin and mucous membranes. Associated nail involvement is underestimated and is characterized by a variety of clinical manifestations. Our aim was to describe the clinical aspects of nail involvement during pemphigus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000501228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883435PMC
November 2019

Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature.

Drugs Context 2019 6;8:212613. Epub 2019 Nov 6.

Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy.

Nail toxicities, such as paronychia and pyogenic granuloma-like lesions, are well-recognized side effects of epidermal growth factor receptor inhibitor (EGFR-I) therapy that can significantly impair patient's quality of life and compliance to anticancer treatment. Numerous therapeutic options are available, with variable rates of success. Recently, topical β-blockers have emerged as a novel, non-invasive treatment strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7573/dic.212613DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860413PMC
November 2019

Group A Streptococcal Paronychia and Blistering Distal Dactylitis in Children: Diagnostic Accuracy of a Rapid Diagnostic Test and Efficacy of Antibiotic Treatment.

J Pediatric Infect Dis Soc 2019 Nov 29. Epub 2019 Nov 29.

Association Clinique et thérapeutique Infantile du Val de Marne, Saint-Maur des Fossés, France.

Among 174 children with blistering distal dactylitis or paronychia, 36.2% had a positive group A Streptococcus (GAS) rapid detection antigen. For GAS, the outcome for patients who received amoxicillin was favorable in all cases without any surgical procedures; 44. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jpids/piz079DOI Listing
November 2019

Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.

Int J Dermatol 2020 Mar 25;59(3):326-332. Epub 2019 Nov 25.

Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Background: Paronychia is a common adverse event caused by epidermal growth factor receptor (EGFR) inhibitors. However, high rates of post-treatment discomfort, infection, recurrence, and increased time to return to work have been noted after nail plate avulsion for EGFR inhibitor-induced paronychia. Furthermore, poor wound healing and malnutrition were common conditions found in cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14730DOI Listing

Squamous cell carcinoma of the nail bed: A case report.

World J Clin Cases 2019 Nov;7(21):3590-3594

Department of Orthopedics, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, Zhejiang Province, China.

Background: Squamous cell carcinoma (SCC) of the nail bed is a poorly reported malignant subungual tumor. Because it presents with nonspecific symptoms and signs, it is frequently misdiagnosed by dermatologists or surgeons. A delay in diagnosis and/or wrong treatment might increase the possibility of disease progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v7.i21.3590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854420PMC
November 2019

Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.

Dermatol Ther 2020 01 15;33(1):e13164. Epub 2019 Nov 15.

Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Paronychia has been described as a side effect in patients undergoing treatment with MEK (mitogen activated protein kinase enzyme) inhibitors. It is usually a recurrent condition that can have a significant impact in the quality of life. Topical beta blocker treatment has been described as an effective therapy in antineoplastic-induced pyogenic granulomas and in antineoplastic-induced paronychia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13164DOI Listing
January 2020

Extract Chemical Composition, Antioxidant Activity and Antifungal Effect against and Causing Onychomycosis.

Molecules 2019 Oct 31;24(21). Epub 2019 Oct 31.

Department of Biology, Faculty of Biology and Geology, Babeș-Bolyai University, 42 Republicii Street, 400015 Cluj-Napoca, Romania.

Onychomycosis is a major health problem due to its chronicity and resistance to therapy. Because some cases associate paronychia, any therapy must target the fungus and the inflammation. Medicinal plants represent an alternative for onychomycosis control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24213958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865177PMC
October 2019

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.

Cancer Chemother Pharmacol 2020 Mar 22;85(3):501-507. Epub 2019 Oct 22.

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Rd, Duarte, CA, 91010, USA.

Purpose: We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem.

Patients: Treating physicians and advanced practice partners identified women who developed infections while on treatment with pertuzumab and trastuzumab alone or in combination with chemotherapy and enrolled them onto this registry trial.

Results: Between March, 2014 and May, 2017, 48 patients with HER2-positive breast cancers were reported to have 59 individual infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03970-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036067PMC
March 2020
1 Read

Paronychia argentea Lam. protects renal endothelial cells against oxidative injury.

J Ethnopharmacol 2020 Feb 17;248:112314. Epub 2019 Oct 17.

Department of Pharmacology, Pharmacognosy and Botany, Faculty of Pharmacy, University Complutense of Madrid, Ciudad Universitaria s/n, 28040, Madrid, Spain. Electronic address:

Ethnopharmacological Relevance: Paronychia argentea Lam. (Arabic tea), a species spontaneously growing in the Mediterranean area, has been used in folk medicine for renal diseases.

Aim Of The Study: To assess the antioxidant and protective potentials of different extracts from P. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jep.2019.112314DOI Listing
February 2020

Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy.

J Cancer 2019 27;10(20):4846-4851. Epub 2019 Aug 27.

Graduate School and School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka, Japan.

: Chemotherapy often results in dermatologic toxicities, which decrease quality of life (QOL) of cancer patients. These adverse skin reactions sometimes happen simultaneously. Though previous reports have demonstrated that skin reactions influence QOL, those reports were focused on only one kind of skin toxicity or on the most serious skin toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.31059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775515PMC

Management and Outcome of Taxane-Induced Nail Side Effects: Experience of 79 Patients from a Single Centre.

Skin Appendage Disord 2019 Aug 22;5(5):276-282. Epub 2019 Mar 22.

Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Background: Nail changes are a common side effect of taxane chemotherapy, although their correct management is poorly standardized.

Objective: To evaluate incidence, clinical aspects, and response to treatment of taxane-induced nail side effects in patients treated with taxanes for malignancies.

Patients And Methods: We performed a retrospective clinical study of 79 patients with taxane-induced nail changes from January 2015 to July 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751462PMC
August 2019
2 Reads

Nail apparatus squamous cell carcinoma mimicking paronychia.

J Dermatol 2019 Dec 9;46(12):e460-e461. Epub 2019 Sep 9.

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15084DOI Listing
December 2019
2 Reads